clinical trial · NCT05063162
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOGAD)
UCB Biopharma SRL·phase3·active not recruiting·n = 113
Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD)RozanolixizumabPlacebo
brief summary
The purpose of the study is to evalute the efficacy, safety and tolerability of rozanolixizumab for treatment of adult participants with myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD).
started
Feb 2, 2022
primary completion
May 6, 2027
completion
Jul 1, 2027
last updated
Sep 25, 2026
official title
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3, Pivotal Study With an Open-Label Extension Period to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-Associated Disease (MOG-AD)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol